We’re excited to announce the results of an important clinical study conducted by ValidCare on CBD: Preliminary results reveal no evidence of liver toxicity.
Since passage of the 2018 Farm Bill, the FDA has been investigating a pathway to regulate the sale of ingestible hemp-derived CBD products. Unfortunately, the agency has not taken any concrete steps, claiming that it needs more real-world data on CBD’s safety profile.
As part of the hemp industry’s continuing effort to provide FDA data, ValidCare commissioned a study and concluded that “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions.”
Major kudos to ValidCare, as well as to the US Hemp Roundtable members who funded and participated in the study: American Shaman, CBDistillery, Charlotte’s Web, Hemp Fusion, Kannaway and Medterra.
Evidence like this confirms that it is high time for FDA to legally recognize and regulate ingestible hemp-derived CBD products. That’s why it’s so important that Congress pass HR 841, which would establish a legal pathway for the sale of hemp-derived extracts as dietary supplements.
Please use our online portal to email your U.S. Representative today, urging him or her to co-sponsor HR 841.
Urge Your Congressperson to Co-Sponsor H.R. 841 (Or Thank Them for Signing On!)Urge Co-Sponsorship!
Take Action In Your State
Make Your Voice Heard
Track the latest hemp and CBD legislative developments in all 50 states and contact your elected representatives to demand action.Go to the State Action Center